Skip to main content
. 2013 Aug 3;3(9):618–632. doi: 10.7150/thno.6810

Fig 1.

Fig 1

Chemical structures of the uPAR targeting ligands: CB-TE2A-AE105, CB-TE2A-PA-AE105 and inactive control peptide CB-TE2A-PA-AE105mut, where Phe→Glu and Trp→Glu replacements grossly impairs the AE105-uPAR binding interface defined by the corresponding X-ray crystal structure 15.